Glidepath Health Launches to Bring Operational Certainty to Cell and Gene Therapy Delivery

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company emerges from stealth with backing from AlleyCorp and A-Squared Ventures, and an exclusive technology license from leading global cancer center

NEW YORK--(BUSINESS WIRE)-- Glidepath Health today emerged from stealth to launch an AI-driven technology platform that orchestrates the complex logistics behind cell and gene therapy delivery. The company also announced an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) covering a suite of patented products and technology, known as ImmunoChain, for complex clinical supply chain logistics developed at MSK.

Cell and gene therapies are among the most operationally demanding treatments in medicine. A single patient journey can span referral, insurance authorization, apheresis scheduling, manufacturing slot assignment, cryogenic shipping, and infusion, with dozens of handoffs across a hospital, a pharmaceutical sponsor, a manufacturing site, and multiple couriers. Compliance requirements today are tracked largely by hand, with critical drug product information documented and reviewed through manual, paper-heavy processes that leave little room for consistency or audit-ready traceability. The consequences reach patients: in a national analysis of commercially insured patients with relapsed or refractory diffuse large B-cell lymphoma, only 5.4% of those eligible for chimeric antigen receptor T-cell (CAR-T) therapy received it.¹

Glidepath Health uses technology and AI to connect the people, systems, and workflows behind every treatment journey. The platform maintains chain of identity and chain of custody from collection through infusion, coordinates apheresis and manufacturing scheduling together rather than sequentially, and gives every party, including the treatment center, sponsor, and manufacturer, a shared, real-time view of the same journey. The result is fewer avoidable delays, less administrative burden on care teams, and more patients moving through the capacity a program already has. This connectivity also gives CGT programs a centralized view of their business so they can track performance, manage resource and capacity utilization, and report quality measures.

"The science behind these therapies is extraordinary. The process around them is not," said Andy Moye, PhD, Chief Executive Officer and Co-Founder of Glidepath Health. "I have spent my career building technology for cancer care, and the pattern is always the same: the breakthrough arrives, and then the delivery system has to catch up. Right now a patient's access to a cell therapy can come down to whether a coordinator managed to line up an apheresis slot and a manufacturing slot in the same week, tracked across a dozen inboxes. That is not a science problem. It is an infrastructure problem, and it is solvable. We started Glidepath Health to build that infrastructure so these therapies are limited by biology, not by administrative complexity."

Under the license agreement, Glidepath Health receives certain exclusive rights to develop and commercialize the ImmunoChain logistics technology. MSK and Glidepath Health are also exploring clinical implementation of the product in their cell therapy program. Financial terms were not disclosed.

“When we began developing ImmunoChain, we saw extraordinary advances in cell and gene therapy being managed through operational processes that simply weren’t built to scale. MSK provided a unique environment to understand these challenges firsthand and develop a provider-driven approach to solving them. I’m proud to see that work become the foundation for Glidepath Health and excited by the opportunity to take what began at MSK and help establish a new standard for how advanced therapies are delivered to patients everywhere,” commented Noah Fichter, MBA, MSK’s Director of Supply Chain Informatics and Business Intelligence.

Glidepath Health is backed by AlleyCorp and A-Squared Ventures, with Omar Njie, MD, Principal at AlleyCorp and Nadav Shimoni, MD, Managing Partner at A-Squared Ventures serving on the company's board of directors.

“What stood out to us was that the missing piece wasn’t another point solution, but the connective tissue across the entire ecosystem,” said Omar Njie, MD, Principal at AlleyCorp. “Andy and the team have lived this problem from both the hospital and industry sides, which gave us conviction to back them before there was a product. We believe Glidepath has the opportunity to become a foundational platform for how advanced therapies are delivered at scale.”

“As we developed our thesis around cell and gene therapies, we found several solutions addressing the needs of insurers and treatment centers, but a clear gap remained for biotech and pharmaceutical companies: no platform was built to connect and orchestrate the entire treatment supply chain,” said Nadav Shimoni, MD, Managing Partner at A-Squared Ventures. “Glidepath is building that connective infrastructure, and the team’s firsthand experience working across pharma, providers, and the broader ecosystem made backing them an easy decision.”

The company is working with leading treatment centers to bring the platform into live patient journeys, with initial deployments planned for this year. The company is also working with major pharma and biotech companies to give them access to critical operational and clinical data and to become their platform of record for advanced therapeutics.

About Glidepath Health

Glidepath Health provides the technology platform that intelligently orchestrates the complex logistics behind cell and gene therapy delivery. By connecting the people, systems, and workflows that make treatment possible, Glidepath Health helps life-changing therapies reach patients safely, reliably, and at scale. Learn more at glidepathhealth.com.

About AlleyCorp

AlleyCorp is a New York-based venture capital firm that incubates and invests in transformative companies across healthcare, AI, enterprise software, consumer tech, deep tech, and more.

As one of the most active early-stage investors in New York, AlleyCorp focuses on investing at the incubation, pre–seed, seed, and Series A stages. Founded by serial entrepreneur Kevin Ryan, AlleyCorp's past incubations have included MongoDB (NASDAQ: MDB), Business Insider, Zola, Gilt Groupe, Radical AI, and Transcend Therapeutics.

About A-Squared Ventures

A² Ventures is a dedicated early-stage digital health fund operating in New York and Tel Aviv. The fund partners with entrepreneurs harnessing software and AI to address unmet needs across the U.S. healthcare system, investing in B2B and B2B2C companies spanning healthcare IT, technology-enabled care delivery, and pharmatech. A² Ventures typically leads or co-leads investments from pre-seed through early Series A.

Disclosure: MSK has institutional financial interests related to this technology and to Glidepath Health.

¹ Ahmed N, et al. Blood Advances 9(18):4727, 2025.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915430311/en/

Media Contact
Esther Moon, Esther@Glidepathhealth.com

Source: Glidepath Health

Key Terms

chimeric antigen receptor t-cell medical

Chimeric antigen receptor T-cell (CAR T-cell) therapy engineers a patient’s own immune cells to recognize and attack specific cancer markers by adding a synthetic receptor; think of it as giving soldiers new, high-precision binoculars to spot hidden targets. It matters to investors because CAR T therapies can offer powerful, sometimes one-time treatments that command premium pricing, drive biotech valuations, and carry risks and costs tied to manufacturing, safety and regulatory approval.

car-t medical

CAR-T is a type of cancer therapy that reprograms a patient’s own immune cells to seek and destroy specific cancer cells, like teaching guard dogs a new scent to track intruders. It matters to investors because CAR-T treatments can command high prices, drive strong revenue for successful developers, and carry regulatory and manufacturing risks that can sharply affect a company’s valuation and long-term growth prospects.

chain of identity technical

A chain of identity is the documented trail that links a specific biological donor or source material to the final medical product or sample at every step of collection, testing, processing and storage. It acts like a chain of custody for tissues, cells or biologics so regulators can verify the product really came from the recorded source and was handled correctly. Investors care because breaches or gaps can trigger product recalls, regulatory sanctions or delays that affect a company’s operations and value.

chain of custody technical

"Chain of custody" is the process of keeping a clear and documented record of how physical or digital evidence is handled, from collection to final use. It ensures that the evidence remains unaltered and trustworthy, much like tracking a package from sender to recipient to confirm it hasn't been tampered with. This is important for investors because it helps verify the integrity and accuracy of information or assets being evaluated.

apheresis medical

Apheresis is a medical process that involves removing specific components, such as blood cells or plasma, from a person's bloodstream and then returning the remaining parts back to their body. It is often used to treat health conditions or collect certain blood products for medical use. For investors, understanding apheresis can be relevant when evaluating companies involved in healthcare, biotechnology, or blood-related therapies, as advancements or changes in this technology can impact market opportunities and healthcare costs.